

RECORDATI: PUBLICATION OF THE INTERIM REPORT FIRST HALF (AS AT 30.06.2026)

Milan, 30th July 2026 – Please be informed that the **Interim Report First Half as at 30th June 2026**, approved on 28th July 2026 by the Board of Directors, as per the press release issued on the same date, to which reference is made, is available to the public, together with **the Independent Auditors' Report on the interim consolidated financial statements as at 30th June 2026**, as of today, at the Company's registered office, on the [Company's website](#) and on the "1INFO" storage mechanism.

[Recordati](#) is an international pharmaceutical Group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. We are uniquely structured to provide treatments across specialty and primary care and rare diseases. Our fully integrated operations span clinical development, manufacturing of active ingredients and finished products, commercialization and licensing. We operate in approximately 150 countries across EMEA, the Americas and APAC, with around 4,700 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose "Unlocking the full potential of life" aims to empower individuals to live life to the fullest, from common conditions to the rarest.

Investor Relations

Eugenia Litz
Eugenia.Litz@recordati.com

Gianluca Saletta
saletta.g@recordati.it

Media Relations

Laura Conti
conti.l@recordati.it

Rebecca Kerr
rebecca.kerr@recordati.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office
Via Matteo Civitali, 1
20148 Milano, Italy
Tel. +39 02 487871
Fax +39 02 40073747
www.recordati.com

Share Capital € 26.140.644,50 fully paid-up
Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150
Tax Code/VAT No. 00748210150
Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.à.r.l